Premium
ABSORPTION OF SULINDAC FROM A NOVEL (PRO‐SORB TM ) LIQUID FORMULATION
Author(s) -
Kanfer I.,
Brown C.,
Konings M.,
Swarbrick J.
Publication year - 1996
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/(sici)1099-081x(199604)17:3<209::aid-bdd956>3.0.co;2-6
Subject(s) - sulindac , cmax , absorption (acoustics) , crossover study , pharmacokinetics , chromatography , chemistry , metabolite , pharmacology , oral administration , high performance liquid chromatography , bioavailability , medicine , biochemistry , materials science , nonsteroidal , alternative medicine , composite material , pathology , placebo
Abstract The absorption of sulindac from two different 200 mg oral dosage forms, Pro‐Sorb TM liquid and Clinoril ® tablets, was compared following administration to eight healthy human volunteers. Subjects received both formulations according to a randomized crossover design and blood samples were collected at selected times during 24 h. Concentrations of both sulindac and its active sulphide metabolite were determined by HPLC and individual serum concentration versus time profiles were constructed. Maximal serum concentrations ( C max ) and area under the curve values (AUC last and AUC 0‐‐∞ ) were compared for both sulindac and sulindac sulphide. The results indicate that the rate and extent of absorption of sulindac from Pro‐Sorb TM liquid are significantly greater than those from Clinoril ® tablets, a finding consistent with the observation that the liquid form produces less gastric irritation following oral administration.